Reflections from EULAR 2026: advancing early control of inflammation UCB Bimekizumab Trumps Risankizumab in Head-to-Head PsA Trial Medscape Late-Breaking Studies at EULAR Paint Rosy Picture of Rheumatology's Future MedPage Today UCB Presents New Long-Term Data on Bimzelx in Psoriatic Arthritis and Axial Spondyloarthritis Idéal Investisseur Bimekizumab Gives Lasting Symptom Relief in PsA Medscape